Fig. 2From: Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trialOutcomes by time to best response. (A, B) The Kaplan-Meier survival curves compare the progression-free survival (A) and the overall survival (B) rates between the patients who reached the best responses shorter and longer than 3.3 months after CAR T cell infusionsBack to article page